Molecular genetics of prostate cancer: Emerging appreciation of genetic complexity

Histopathology

Volumn 60, Issue 1, 2012, Pages 187-198

  Barbieri, Christopher E ^a   Demichelis, Francesca ^b   Rubin, Mark A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

Gene rearrangements; Genetics; Mutation; Prostate cancer; TMPRSS2:ERG fusion; Whole genome sequencing

Indexed keywords

ABIRATERONE ACETATE; CETUXIMAB; DOXORUBICIN; ETOPOSIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; CANCER SUSCEPTIBILITY; CASTRATION RESISTANT PROSTATE CANCER; COPY NUMBER VARIATION; DISEASE COURSE; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; NEEDLE BIOPSY; NONSENSE MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

GENETIC VARIATION; GENOME, HUMAN; GENOMICS; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84255199166     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04041.x     Document Type: Review

References (113)

1. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 2011; 29; 3659-3668.
2. Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv. Anat. Pathol. 2008; 15; 319-331.
3. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310; 644-648.
4. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66; 8337-8341.
5. Tomlins SA, Mehra R, Rhodes DR et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 2006; 66; 3396-3400.
6. Demichelis F, Setlur SR, Beroukhim R et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosom. Cancer 2009; 48; 366-380.
7. Lapointe J, Li C, Giacomini CP et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007; 67; 8504-8510.
8. Lapointe J, Li C, Higgins JP et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 2004; 101; 811-816.
9. Setlur SR, Mertz KD, Hoshida Y et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl Cancer Inst. 2008; 100; 815-825.
10. Taylor BS, Schultz N, Hieronymus H et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18; 11-22.
11. Ateeq B, Tomlins SA, Laxman B et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci. Transl. Med. 2011; 3; 72ra17.
12. Kan Z, Jaiswal BS, Stinson J et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466; 869-873.
13. Berger MF, Lawrence MS, Demichelis F et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470; 214-220.
14. Forbes SA, Tang G, Bindal N et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 2010; 38; D652-D657.
15. Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. E17K substitution in AKT1 in prostate cancer. Br. J. Cancer 2010; 102; 1491-1494.
16. Bentley DR, Balasubramanian S, Swerdlow HP et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 2008; 456; 53-59.
17. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437; 376-380.
18. Shendure J, Porreca GJ, Reppas NB et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 2005; 309; 1728-1732.
19. Smith DR, Quinlan AR, Peckham HE et al. Rapid whole-genome mutational profiling using next-generation sequencing technologies. Genome Res. 2008; 18; 1638-1642.
20. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat. Rev. 2008; 8; 497-511.
21. Maher CA, Kumar-Sinha C, Cao X et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458; 97-101.
22. Gingeras TR. Implications of chimaeric non-co-linear transcripts. Nature 2009; 461; 206-211.
23. Pflueger D, Terry S, Sboner A et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2011; 21; 56-67.
24. Sboner A, Habegger L, Pflueger D et al. FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biol. 2010; 11; R104.
25. Makkonen H, Kauhanen M, Paakinaho V, Jaaskelainen T, Palvimo JJ. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res. 2009; 37; 4135-4148.
26. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 2008; 68; 3094-3098.
27. Ross LE, Berkowitz Z, Ekwueme DU. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol. Biomarkers Prev. 2008; 17; 636-644.
28. Grubb RL III, Pinsky PF, Greenlee RT et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008; 102; 1524-1530.
29. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360; 1320-1328.
30. Lucia MS, Darke AK, Goodman PJ et al. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev. Res. (PA) 2008; 1; 167-173.
31. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0ng per milliliter. N. Engl. J. Med. 2004; 350; 2239-2246.
32. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J. Natl Cancer Inst. 2006; 98; 529-534.
33. Nam RK, Toi A, Klotz LH et al. Assessing individual risk for prostate cancer. J. Clin. Oncol. 2007; 25; 3582-3588.
34. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl Cancer Inst. 2009; 101; 374-383.
35. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J. Natl Cancer Inst. 2002; 94; 981-990.
36. Andriole GL, Grubb RL III, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009; 360; 1310-1319.
37. Leary RJ, Kinde I, Diehl F et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2010; 2; 20ra14.
38. Tomlins SA, Bjartell A, Chinnaiyan AM et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 2009; 56; 275-286.
39. Furusato B, Tan SH, Young D et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010; 13; 228-237.
40. Park K, Tomlins SA, Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12; 590-598.
41. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59; 5975-5979.
42. Deras IL, Aubin SM, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 2008; 179; 1587-1592.
43. Groskopf J, Aubin SM, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 2006; 52; 1089-1095.
44. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 2007; 13; 5103-5108.
45. Laxman B, Morris DS, Yu J et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008; 68; 645-649.
46. Laxman B, Tomlins SA, Mehra R et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006; 8; 885-888.
47. Nilsson J, Skog J, Nordstrand A et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 2009; 100; 1603-1607.
48. Rostad K, Hellwinkel OJ, Haukaas SA et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009; 117; 575-582.
49. Tomlins SA, Aubin SM, Siddiqui J et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 2011; 3; 94ra72.
50. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 1994; 50; 267-273.
51. Attard G, Swennenhuis JF, Olmos D et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009; 69; 2912-2918.
52. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 2008; 69; 2912-2918.
53. Palanisamy N, Ateeq B, Kalyana-Sundaram S et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat. Med. 2010; 16; 793-798.
54. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008; 7; 3129-3140.
55. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008; 14; 4275-4283.
56. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448; 561-566.
57. Frayne J, Hurd EA, Hall L. Human tMDC III: a sperm protein with a potential role in oocyte recognition. Mol. Hum. Reprod. 2002; 8; 817-822.
58. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. 2008; 8; 929-941.
59. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006; 75; 271-294.
60. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 2008; 410; 439-453.
61. Mani RS, Chinnaiyan AM. Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. Nat. Rev. Genet. 2010; 11; 819-829.
62. Ju BG, Lunyak VV, Perissi V et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 2006; 312; 1798-1802.
63. Haffner MC, Aryee MJ, Toubaji A et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010; 42; 668-675.
64. Bastus NC, Boyd LK, Mao X et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 2010; 70; 9544-9548.
65. Lin C, Yang L, Tanasa B et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139; 1069-1083.
66. Mani RS, Tomlins SA, Callahan K et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009; 326; 1230.
67. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275; 1943-1947.
68. Wu X, Hepner K, Castelino-Prabhu S et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl Acad. Sci. USA 2000; 97; 4233-4238.
69. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 2001; 276; 48627-48630.
70. Han B, Mehra R, Lonigro RJ et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod. Pathol. 2009; 22; 1083-1093.
71. Carver BS, Tran J, Gopalan A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 2009; 41; 619-624.
72. King JC, Xu J, Wongvipat J et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009; 41; 524-526.
73. Nagai Y, Kojima T, Muro Y et al. Identification of a novel nuclear speckle-type protein, SPOP. FEBS Lett. 1997; 418; 23-26.
74. Hernandez-Munoz I, Lund AH, van der Stoop P et al. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc. Natl Acad. Sci. USA 2005; 102; 7635-7640.
75. Zhuang M, Calabrese MF, Liu J et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 2009; 36; 39-50.
76. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 2000; 343; 78-85.
77. Amundadottir LT, Sulem P, Gudmundsson J et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 2006; 38; 652-658.
78. Freedman ML, Haiman CA, Patterson N et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc. Natl Acad. Sci. USA 2006; 103; 14068-14073.
79. Eeles RA, Kote-Jarai Z, Al Olama AA et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 2009; 41; 1116-1121.
80. Eeles RA, Kote-Jarai Z, Giles GG et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 2008; 40; 316-321.
81. Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 2008; 40; 310-315.
82. Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 2008; 358; 910-919.
83. Duggan D, Zheng SL, Knowlton M et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl Cancer Inst. 2007; 99; 1836-1844.
84. Xu J, Zheng SL, Isaacs SD et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc. Natl Acad. Sci. USA 2010; 107; 2136-2140.
85. Cheng I, Plummer SJ, Neslund-Dudas C et al. Prostate cancer susceptibility variants confer increased risk of disease progression. Cancer Epidemiol. Biomarkers Prev. 2010; 19; 2124-2132.
86. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin. Cancer Res. 2008; 14; 3823-3831.
87. Holt SK, Kwon EM, Koopmeiners JS et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010; 70; 1448-1460.
88. Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate 2010; 70; 1012-1019.
89. Huang SP, Ting WC, Chen LM et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann. Surg. Oncol. 2010; 17; 312-322.
90. Nguyen PL, Ma J, Chavarro JE et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J. Clin. Oncol. 2010; 28; 3958-3964.
91. Wright JL, Kwon EM, Lin DW et al. CYP17 polymorphisms and prostate cancer outcomes. Prostate 2010; 70; 1094-1101.
92. Gallagher DJ, Vijai J, Cronin AM et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin. Cancer Res. 2010; 16; 2819-2832.
93. Lin DW, Fitzgerald LM, Fu R et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol. Biomarkers Prev. 2011; 20; 954-961.
94. Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum. Mol. Genet. 2006; 15 (Spec. no. 1); R57-R66.
95. Freeman JL, Perry GH, Feuk L et al. Copy number variation: new insights in genome diversity. Genome Res. 2006; 16; 949-961.
96. Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the human genome. Nature 2006; 444; 444-454.
97. McCarroll SA, Kuruvilla FG, Korn JM et al. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat. Genet. 2008; 40; 1166-1174.
98. Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annu. Rev. Med. 2010; 61; 437-455.
99. Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human health, disease, and evolution. Annu. Rev. Genomics Hum. Genet. 2009; 10; 451-481.
100. Banerjee S, Oldridge D, Poptsova M, Hussain WM, Chakravarty D, Demichelis F. A computational framework discovers new copy number variants with functional importance. PLoS ONE 2011; 6; e17539.
101. Conrad DF, Pinto D, Redon R et al. Origins and functional impact of copy number variation in the human genome. Nature 2010; 464; 704-712.
102. Mills RE, Walter K, Stewart C et al. Mapping copy number variation by population-scale genome sequencing. Nature 2011; 470; 59-65.
103. Stranger BE, Forrest MS, Dunning M et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007; 315; 848-853.
104. Diskin SJ, Hou C, Glessner JT et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009; 459; 987-991.
105. Shlien A, Tabori U, Marshall CR et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc. Natl Acad. Sci. USA 2008; 105; 11264-11269.
106. Korbel JO, Kim PM, Chen X et al. The current excitement about copy-number variation: how it relates to gene duplications and protein families. Curr. Opin. Struct. Biol. 2008; 18; 366-374.
107. Cybulski C, Wokolorczyk D, Huzarski T et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J. Med. Genet. 2006; 43; 863-866.
108. Gallagher CJ, Kadlubar FF, Muscat JE, Ambrosone CB, Lang NP, Lazarus P. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians. Cancer Detect. Prev. 2007; 31; 310-315.
109. Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstrom L. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J. 2008; 8; 147-151.
110. Olsson M, Lindstrom S, Haggkvist B et al. The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate 2008; 68; 571-575.
111. Park J, Chen L, Ratnashinge L et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol. Biomarkers Prev. 2006; 15; 1473-1478.
112. Setlur SR, Chen CX, Hossain RR et al. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2010; 19; 229-239.
113. Bartsch G, Horninger W, Klocker H et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008; 101; 809-816.